ライフサイエンスコーパス: juvenile idiopathic arthritis

1 ciated with uveitis also are idiopathic (eg, juvenile idiopathic arthritis).

2 tones risk; and between immunoglobulin A and juvenile idiopathic arthritis).

3 id arthritis, spondyloarthritis and systemic juvenile idiopathic arthritis.

4 sease, leprosy, Behcet disease, and systemic juvenile idiopathic arthritis.

5 been made in the measurement of outcomes in juvenile idiopathic arthritis.

6 t rheumatoid arthritis might have utility in juvenile idiopathic arthritis.

7 idity and mortality seen with systemic onset juvenile idiopathic arthritis.

8 redominantly in children with systemic onset juvenile idiopathic arthritis.

9 ry outcome measures in therapeutic trials in juvenile idiopathic arthritis.

10 ic arthritis (SoJIA) represents up to 20% of juvenile idiopathic arthritis.

11 diopathic uveitis or uveitis associated with juvenile idiopathic arthritis.

12 ophage activation syndrome in systemic onset juvenile idiopathic arthritis.

13 omandibular joint arthritis in children with juvenile idiopathic arthritis.

14 11 years, range 4-16), of whom 37 (74%) had juvenile idiopathic arthritis.

15 edict temporomandibular joint involvement in juvenile idiopathic arthritis.

16 access to effective treatments and care for juvenile idiopathic arthritis.

17 f S100A12 correlate with disease activity in juvenile idiopathic arthritis.

18 2001on the matter of uveitis associated with juvenile idiopathic arthritis.

19 Of the 52 children with CAU, 75% had juvenile idiopathic arthritis.

20 givinostat, an approved therapy for systemic juvenile idiopathic arthritis.

21 e inhibitor, versus placebo in patients with juvenile idiopathic arthritis.

22 ammatory diseases such as sepsis or systemic juvenile idiopathic arthritis.

23 isk of lower respiratory tract infection and juvenile idiopathic arthritis.

24 as been used to treat children with systemic juvenile idiopathic arthritis.

25 he interleukin-1 signature in systemic onset juvenile idiopathic arthritis.

26 compromise the resolution of inflammation in juvenile idiopathic arthritis.

27 tionally is classified under the umbrella of juvenile idiopathic arthritis.

28 anti-citrullinated protein antibody-positive juvenile idiopathic arthritis.

29 anti-citrullinated protein antibody-positive juvenile idiopathic arthritis.

30 entres to enrol children with a diagnosis of juvenile idiopathic arthritis, according to Internationa

31 atic diseases, such as rheumatoid arthritis, juvenile idiopathic arthritis, adult-onset Still's disea

32 ocular morbidity of uveitis associated with juvenile idiopathic arthritis, aggressive therapies can

33 ackground rate of malignancy associated with juvenile idiopathic arthritis, although the impact of me

34 Patients meeting Juvenile Idiopathic Arthritis-American College of Rheuma

35 losing spondylitis, psoriatic arthritis, and juvenile idiopathic arthritis among the inflammatory joi

36 ced in monocytes from patients with systemic juvenile idiopathic arthritis, an autoinflammatory disea

37 We present a case of systemic juvenile idiopathic arthritis, an autoinflammatory disea

38 A 14-year-old female with systemic juvenile idiopathic arthritis and a history of bilateral

39 lammatory syndrome that encompasses systemic juvenile idiopathic arthritis and adult-onset Still's di

40 ed with biologic agents for the treatment of juvenile idiopathic arthritis and childhood-onset system

41 The diagnoses of juvenile idiopathic arthritis and childhood-onset system

42 recognized in children and young adults with juvenile idiopathic arthritis and is multifactorial in o

43 rsity before and after HSCT in patients with juvenile idiopathic arthritis and juvenile dermatomyosit

44 In rheumatoid arthritis, juvenile idiopathic arthritis and other forms of inflamm

45 aired in a large proportion of children with juvenile idiopathic arthritis and other rheumatic diseas

46 de has been utilized to treat systemic onset juvenile idiopathic arthritis and related autoinflammato

47 tive diseases, significantly most similar to juvenile idiopathic arthritis and significantly least si

48 tes and synechiae, and systemic diagnoses of juvenile idiopathic arthritis and spondyloarthropathy pr

49 Systemic diagnosis with juvenile idiopathic arthritis and spondyloarthropathy we

50 ary biliary cirrhosis, rheumatoid arthritis, juvenile idiopathic arthritis, and alopecia areata.

51 itions, and preliminary quality measures for juvenile idiopathic arthritis, and cites examples of qua

52 hildhood-onset systemic lupus erythematosus, juvenile idiopathic arthritis, and juvenile dermatomyosi

53 hildhood-onset systemic lupus erythematosus, juvenile idiopathic arthritis, and juvenile dermatomyosi

54 60% were female, approximately half had juvenile idiopathic arthritis, and most were treated wit

55 MIS-C, compared with dengue virus infection, juvenile idiopathic arthritis, and pediatric celiac dise

56 ty of life in large cohorts of children with juvenile idiopathic arthritis are important in guiding i

57 The aims of treating juvenile idiopathic arthritis are to elicit treatment re

58 tic reports of the use of bisphosphonates in juvenile idiopathic arthritis are welcome additions to t

59 re rheumatic diseases, most notably systemic juvenile idiopathic arthritis, are at risk for MAS.

60 ase pathogenesis of lupus and systemic onset juvenile idiopathic arthritis as well as related conditi

61 stic terms had differences in ICD-10 coding: juvenile idiopathic arthritis associated chronic uveitis

62 ation with MethOtRExate for the treatment of juvenile idiopathic arthritis associated uveitis) trial

63 to be an effective therapy for patients with juvenile idiopathic arthritis-associated RV or those who

64 ctors, and course of ocular hypotony (OH) in juvenile idiopathic arthritis-associated uveitis (JIAU).

65 ses were birdshot chorioretinopathy (n = 3), juvenile idiopathic arthritis-associated uveitis (n = 3)

66 Patients with juvenile idiopathic arthritis-associated uveitis had poo

67 -Hispanic African-American children with non-juvenile idiopathic arthritis-associated uveitis may hav

68 Many cases of juvenile idiopathic arthritis-associated uveitis, many c

69 setting of certain forms of uveitis, such as juvenile idiopathic arthritis-associated uveitis, remain

70 Adalimumab is an effective treatment for juvenile idiopathic arthritis-associated uveitis.

71 both in patients with previously controlled juvenile idiopathic arthritis-associated uveitis.

72 of discontinuing treatment in patients with juvenile idiopathic arthritis-associated uveitis.

73 As the pathogenesis of juvenile idiopathic arthritis becomes better understood,

74 the incidence of malignancy associated with juvenile idiopathic arthritis, both with and without tre

75 itis had poorer HRQoL scores than nonuveitic juvenile idiopathic arthritis by 5.26 (95% confidence in

76 Juvenile idiopathic arthritis can be refractory to some

77 related protein-14 (S100A9) in children with juvenile idiopathic arthritis can indicate clinically oc

78 Juvenile idiopathic arthritis continues to provide probl

79 A 46-year-old man with juvenile idiopathic arthritis developed a pruritic cutan

80 diopathic arthritis, extended oligoarticular juvenile idiopathic arthritis, enthesitis-related arthri

81 rheumatoid factor), extended oligoarticular juvenile idiopathic arthritis, enthesitis-related arthri

82 ty profile in the treatment of polyarticular juvenile idiopathic arthritis, extended oligoarticular j

83 lity of new medications for the treatment of juvenile idiopathic arthritis has made the accurate asse

84 ith rheumatoid factor positive polyarticular juvenile idiopathic arthritis, have the greatest deficit

85 In juvenile idiopathic arthritis, heat shock proteins have

86 with seronegative spondyloarthropathies and juvenile idiopathic arthritis; however, etanercept has f

87 1.14, 95% CI [0.96, 1.35], p-value = 0.132), juvenile idiopathic arthritis (HR 1.02, 95% CI [0.85, 1.

88 5, 95% CI [0.88, 1.26], p-value = 0.594) and juvenile idiopathic arthritis (HR 1.11, 95% CI [0.93, 1.

89 The most common causes were juvenile idiopathic arthritis in 39 patients, pars plani

90 on electrode, aiming at the diagnosis of the juvenile idiopathic arthritis in real serum samples.

91 tumor necrosis factor-alpha inhibitors has a juvenile idiopathic arthritis indication.

92 interest were the onset of type 1 diabetes, juvenile idiopathic arthritis, inflammatory bowel diseas

93 The armamentarium for treatment of juvenile idiopathic arthritis is expanding at a rapid ra

94 tivity in the development of osteoporosis in juvenile idiopathic arthritis is the focus of several st

95 Juvenile idiopathic arthritis is the most common chronic

96 ), fulfillment of criteria for >1 subtype of juvenile idiopathic arthritis (JIA) (5%), and HLA-B27 in

97 about exercise therapy in the management of juvenile idiopathic arthritis (JIA) along with activity

98 dministered to children and adolescents with juvenile idiopathic arthritis (JIA) and pediatric inflam

99 ination on disease activity in patients with juvenile idiopathic arthritis (JIA) are matters of conce

100 Juvenile idiopathic arthritis (JIA) can persist through

101 Juvenile idiopathic arthritis (JIA) commonly affects the

102 Juvenile idiopathic arthritis (JIA) comprises several cl

103 Uveitis associated with juvenile idiopathic arthritis (JIA) continues to blind s

104 olyarticular rheumatoid factor (RF)-negative juvenile idiopathic arthritis (JIA) due to the presence

105 a in multiple autoimmune diseases, including juvenile idiopathic arthritis (JIA) has earned substanti

106 In the past two decades, the treatment of juvenile idiopathic arthritis (JIA) has evolved markedly

107 loci in oligoarthritis in UK Caucasians with juvenile idiopathic arthritis (JIA) has not been describ

108 Patients with systemic juvenile idiopathic arthritis (JIA) have arthritis, quot

109 The chronicity of juvenile idiopathic arthritis (JIA) into adulthood and a

110 ciations for Rheumatology criteria parse out juvenile idiopathic arthritis (JIA) into seven groups, w

111 Juvenile idiopathic arthritis (JIA) is a chronic rheumat

112 Juvenile idiopathic arthritis (JIA) is a heterogeneous g

113 Juvenile idiopathic arthritis (JIA) is a wide group of d

114 Juvenile idiopathic arthritis (JIA) is an autoimmune dis

115 Systemic juvenile idiopathic arthritis (JIA) is an autoinflammato

116 predict response to therapy in polyarticular juvenile idiopathic arthritis (JIA) is an important issu

117 Juvenile idiopathic arthritis (JIA) is an umbrella term

118 Assessment of this association in juvenile idiopathic arthritis (JIA) is complicated by ag

119 Systemic juvenile idiopathic arthritis (JIA) is frequently associ

120 Juvenile idiopathic arthritis (JIA) is one of the most c

121 Juvenile Idiopathic Arthritis (JIA) is one of the most c

122 Systemic juvenile idiopathic arthritis (JIA) is the most severe s

123 The pathogenesis of juvenile idiopathic arthritis (JIA) is thought to involv

124 isease classification separately, yielding a juvenile idiopathic arthritis (JIA) nomenclature that ex

125 ing arthritis in pediatric participants with juvenile idiopathic arthritis (JIA) or suspected of havi

126 oved prospective study, 45 participants with juvenile idiopathic arthritis (JIA) or suspected of havi

127 In juvenile idiopathic arthritis (JIA) patients, we have pr

128 Juvenile idiopathic arthritis (JIA) refers to a collecti

129 Eight children with juvenile idiopathic arthritis (JIA) served as controls.

130 Subtypes of juvenile idiopathic arthritis (JIA) share phenotypic fea

131 concentrations in a cohort of patients with juvenile idiopathic arthritis (JIA) to determine the pre

132 aluations of the well-being of children with juvenile idiopathic arthritis (JIA) typically rely on pa

133 amily in which 9 members were diagnosed with juvenile idiopathic arthritis (JIA) was ascertained.

134 n this work, a novel biosensor for detecting juvenile idiopathic arthritis (JIA) was developed based

135 An association with juvenile idiopathic arthritis (JIA) was seen in 0.3% of

136 ty of dentofacial deformity in patients with juvenile idiopathic arthritis (JIA), and to perform a va

137 y reported to be a characteristic feature of juvenile idiopathic arthritis (JIA), but the relevance o

138 chip array to analyze 2,816 individuals with juvenile idiopathic arthritis (JIA), comprising the most

139 in patients with the most common subtypes of juvenile idiopathic arthritis (JIA), IgM rheumatoid fact

140 diseases in the UK population, including RA, juvenile idiopathic arthritis (JIA), psoriasis, psoriati

141 ultifactorial diseases, including autoimmune juvenile idiopathic arthritis (JIA), result from a compl

142 In juvenile idiopathic arthritis (JIA), there are now more

143 S on children with the polyarticular form of juvenile idiopathic arthritis (JIA), using 2 independent

144 association study of Caucasian patients with juvenile idiopathic arthritis (JIA), we have previously

145 of cataract development among patients with juvenile idiopathic arthritis (JIA)-associated uveitis t

146 t evidence from the literature pertaining to juvenile idiopathic arthritis (JIA)-associated uveitis.

147 and autoantigen in a subset of children with juvenile idiopathic arthritis (JIA).

148 is (RA) and other rheumatic diseases such as juvenile idiopathic arthritis (JIA).

149 il activation in children with polyarticular juvenile idiopathic arthritis (JIA).

150 MTX) in children with selected categories of juvenile idiopathic arthritis (JIA).

151 thin the IL2RA/CD25 gene are associated with juvenile idiopathic arthritis (JIA).

152 e gene that causes diastrophic dysplasia, in juvenile idiopathic arthritis (JIA).

153 ge activation syndrome complicating systemic juvenile idiopathic arthritis (JIA).

154 RhMDT) assessment for children with incident juvenile idiopathic arthritis (JIA).

155 h the fever and disease activity of systemic juvenile idiopathic arthritis (JIA).

156 umatoid arthritis (RA), and 19 subjects with juvenile idiopathic arthritis (JIA).

157 ears further defining the pathophysiology of juvenile idiopathic arthritis (JIA).

158 ing and joint-derived Tregs and non-Tregs in juvenile idiopathic arthritis (JIA).

159 affected by inflammatory arthritis, known as juvenile idiopathic arthritis (JIA).

160 ciation between cow's milk allergy (CMA) and juvenile idiopathic arthritis (JIA).

161 arthritis (RA), spondyloarthritis (SpA), and juvenile idiopathic arthritis (JIA).

162 lacebo in patients with polyarticular course juvenile idiopathic arthritis (JIA).

163 is one of the most common manifestations of juvenile idiopathic arthritis (JIA).

164 l antibody, is effective in the treatment of juvenile idiopathic arthritis (JIA).

165 is abundant in the synovia of patients with juvenile idiopathic arthritis (JIA).

166 e and are associated with innate immunity in juvenile idiopathic arthritis (JIA).

167 1 is pivotal in the pathogenesis of systemic juvenile idiopathic arthritis (JIA).

168 ociated with a rare group of diseases called juvenile idiopathic arthritis (JIA).

169 and autoantigen in a subset of children with juvenile idiopathic arthritis (JIA).

170 trated that there is familial aggregation of juvenile idiopathic arthritis (JIA).

171 ate (MTX) are unpredictable in patients with juvenile idiopathic arthritis (JIA).

172 cted coarctation of the aorta (CoA, n = 25), juvenile idiopathic arthritis (JIA, n = 20), obesity (OB

173 Systemic diagnoses with juvenile idiopathic arthritis (JIA; adjusted hazard rati

174 associated with increased risk for systemic juvenile idiopathic arthritis, leprosy and Crohn's disea

175 in weight-bearing cartilage in patients with juvenile idiopathic arthritis may help with early detect

176 approved dosage for rheumatoid arthritis and juvenile idiopathic arthritis, may be an effective treat

177 tients with uveitic glaucoma associated with juvenile idiopathic arthritis (n = 20), idiopathic uveit

178 identified: Crohn's disease (n = 8; 42%) and juvenile idiopathic arthritis (n = 6; 32%) were the comm

179 ases associated with uveitis-related CME are juvenile idiopathic arthritis (n = 9), Behcet disease (n

180 1 diabetes (n = 9), celiac disease (n = 24), juvenile idiopathic arthritis (n = 9), inflammatory bowe

181 re identified; Crohn's disease (n=8;42%) and juvenile idiopathic arthritis (n=6;32%) were the commone

182 years) with a CMC, such as type 1 diabetes, juvenile idiopathic arthritis, or inflammatory bowel dis

183 iseases (namely, inflammatory bowel disease, juvenile idiopathic arthritis, or psoriasis) or a nonimm

184 e in the literature demonstrating a systemic juvenile idiopathic arthritis patient presenting with fr

185 NK cells isolated from the synovial fluid of juvenile idiopathic arthritis patients failed to inhibit

186 ophage activation syndrome in systemic onset juvenile idiopathic arthritis patients.

187 ed muscle mass and abnormal bone geometry in juvenile idiopathic arthritis patients.

188 +) monocytes exposed to plasma from systemic juvenile idiopathic arthritis patients.

189 nts presented with cutaneous tumid lupus and juvenile idiopathic arthritis plus neuroinflammatory dis

190 nts (aged 2 to <18 years) with polyarticular juvenile idiopathic arthritis (positive or negative for

191 celiac disease, inflammatory bowel disease, juvenile idiopathic arthritis, psoriasis, type 1 diabete

192 (SF) from patients with osteoarthritis (OA), juvenile idiopathic arthritis, psoriatic arthritis (PsA)

193 The majority of patients with juvenile idiopathic arthritis-related uveitic glaucoma r

194 re was achieved in the eyes of patients with juvenile idiopathic arthritis-related uveitis glaucoma w

195 ing of the risk factors for poor outcomes in juvenile idiopathic arthritis-related uveitis.

196 e far more costly than that of adult SLE and juvenile idiopathic arthritis reported in the literature

197 Meanwhile, novel studies of systemic-onset juvenile idiopathic arthritis reveal a strong HLA associ

198 eitis in children are highlighted, including juvenile idiopathic arthritis, sarcoidosis and Behcet's

199 ned from the synovial fluid of patients with juvenile idiopathic arthritis show marked downregulation

200 are often observed in children with systemic juvenile idiopathic arthritis (sJIA) and cytokine storm

201 across disparate entities including systemic juvenile idiopathic arthritis (sJIA) and its counterpart

202 ith inflammatory disorders, such as systemic juvenile idiopathic arthritis (SJIA) and macrophage acti

203 rs most frequently in patients with systemic juvenile idiopathic arthritis (SJIA) and systemic lupus

204 Systemic juvenile idiopathic arthritis (SJIA) is an inflammatory

205 l RNA-Seq of PBMCs of patients with systemic juvenile idiopathic arthritis (SJIA) with diverse clinic

206 FA-challenged IFN-gamma KO resemble systemic juvenile idiopathic arthritis (sJIA), a childhood immune

207 When applied to systemic juvenile idiopathic arthritis (sJIA), an autoinflammator

208 escent from the United Kingdom with systemic juvenile idiopathic arthritis (sJIA), with the GG genoty

209 his review summarizes biomarkers in systemic juvenile idiopathic arthritis (sJIA).

210 y, is most strongly associated with systemic juvenile idiopathic arthritis (SJIA).

211 r cells from children with inactive systemic juvenile idiopathic arthritis (sJIA, n = 17), active sJI

212 Systemic onset juvenile idiopathic arthritis (SoJIA) encompasses approx

213 Systemic onset juvenile idiopathic arthritis (SoJIA) represents up to 2

214 ation is now also reported in systemic onset juvenile idiopathic arthritis (SoJIA).

215 pivotal trial of infliximab in polyarticular juvenile idiopathic arthritis suggested efficacy, but th

216 The disorders reviewed are juvenile idiopathic arthritis, systemic lupus erythemato

217 osed rheumatic diseases in children, such as juvenile idiopathic arthritis, systemic lupus erythemato

218 in treating chronic uveitis associated with juvenile idiopathic arthritis than etanercept.

219 more frequent manifestation in patients with juvenile idiopathic arthritis than previously believed,

220 In the inflammatory site in human juvenile idiopathic arthritis, the CD39(+)Foxp3(-) popul

221 In patients with juvenile idiopathic arthritis, this apparent 'immune pri

222 charged with developing quality measures for juvenile idiopathic arthritis; thus, there is a commitme

223 iments, the addition of NGF to LPS-activated juvenile idiopathic arthritis to both mononuclear cells

224 ortant; no child should be labeled as having juvenile idiopathic arthritis unless there is a clear hi

225 rior uveitis, posterior synechiae, cataract, juvenile idiopathic arthritis, visual acuity, tobacco ex

226 g cholangitis, primary biliary cirrhosis and juvenile idiopathic arthritis, were obtained from publis

227 ciated at the inflamed site in patients with juvenile idiopathic arthritis, which led us to question

228 In patients with juvenile idiopathic arthritis who do not respond to oral

229 ic illness and rheumatic conditions, such as juvenile idiopathic arthritis, who demonstrated no socia

230 of personalised medicine in the treatment of juvenile idiopathic arthritis will be aided with interna

231 modifying antirheumatoid drugs for suspected juvenile idiopathic arthritis, without any clinical bene